| Dr Barry I Auster, MD | |
|
31275 Northwestern Hwy Ste 140, Farmington Hills, MI 48334-2531 | |
| (248) 538-0109 | |
| (248) 538-0675 |
| Full Name | Dr Barry I Auster |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 50 Years |
| Location | 31275 Northwestern Hwy Ste 140, Farmington Hills, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255323341 | NPI | - | NPPES |
| 070F358740 | Other | MI | BCBSM |
| 0636848 | Other | MI | BCBSM |
| 791073153A | Other | MI | MEDICARE RAILROAD |
| 0706364961 | Other | MI | BCBSM |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 4301039912 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Joseph Mercy Hospital | Ann arbor, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Iha Health Services Corporation | 2466351440 | 911 |
News Archive
AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients.
Viron Therapeutics Inc., a biotechnology company pioneering the development of immune-modulating protein therapeutics derived from pathogens, today reported results from a Phase IIa clinical trial evaluating VT-111 (Serp-1), an anti-inflammatory protein derived from the myxoma virus.
Spherix Incorporated reported that patient recruitment for its Phase 3 clinical trial of its potential type 2 diabetes drug, Naturlose, has begun in India. Expectations for India are to provide more than 300 patients spread across 35 sites for the pivotal Phase 3 trial.
A translational research team led by the National University of Singapore has harnessed CURATE.AI, a powerful artificial intelligence platform, to successfully treat a patient with advanced cancer, completely halting disease progression. This new development represents a big step forward in personalized medicine.
› Verified 7 days ago
| Entity Name | Iha Health Services Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457408965 PECOS PAC ID: 2466351440 Enrollment ID: O20040108000355 |
News Archive
AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients.
Viron Therapeutics Inc., a biotechnology company pioneering the development of immune-modulating protein therapeutics derived from pathogens, today reported results from a Phase IIa clinical trial evaluating VT-111 (Serp-1), an anti-inflammatory protein derived from the myxoma virus.
Spherix Incorporated reported that patient recruitment for its Phase 3 clinical trial of its potential type 2 diabetes drug, Naturlose, has begun in India. Expectations for India are to provide more than 300 patients spread across 35 sites for the pivotal Phase 3 trial.
A translational research team led by the National University of Singapore has harnessed CURATE.AI, a powerful artificial intelligence platform, to successfully treat a patient with advanced cancer, completely halting disease progression. This new development represents a big step forward in personalized medicine.
› Verified 7 days ago
| Entity Name | Midwest Center For Dermatology & Pathology Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003095084 PECOS PAC ID: 0446330492 Enrollment ID: O20080103000679 |
News Archive
AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients.
Viron Therapeutics Inc., a biotechnology company pioneering the development of immune-modulating protein therapeutics derived from pathogens, today reported results from a Phase IIa clinical trial evaluating VT-111 (Serp-1), an anti-inflammatory protein derived from the myxoma virus.
Spherix Incorporated reported that patient recruitment for its Phase 3 clinical trial of its potential type 2 diabetes drug, Naturlose, has begun in India. Expectations for India are to provide more than 300 patients spread across 35 sites for the pivotal Phase 3 trial.
A translational research team led by the National University of Singapore has harnessed CURATE.AI, a powerful artificial intelligence platform, to successfully treat a patient with advanced cancer, completely halting disease progression. This new development represents a big step forward in personalized medicine.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Barry I Auster, MD 24 Frank Lloyd Wright Dr Lbby J2000, Ann Arbor, MI 48105-9484 Ph: (734) 747-6766 | Dr Barry I Auster, MD 31275 Northwestern Hwy Ste 140, Farmington Hills, MI 48334-2531 Ph: (248) 538-0109 |
News Archive
AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients.
Viron Therapeutics Inc., a biotechnology company pioneering the development of immune-modulating protein therapeutics derived from pathogens, today reported results from a Phase IIa clinical trial evaluating VT-111 (Serp-1), an anti-inflammatory protein derived from the myxoma virus.
Spherix Incorporated reported that patient recruitment for its Phase 3 clinical trial of its potential type 2 diabetes drug, Naturlose, has begun in India. Expectations for India are to provide more than 300 patients spread across 35 sites for the pivotal Phase 3 trial.
A translational research team led by the National University of Singapore has harnessed CURATE.AI, a powerful artificial intelligence platform, to successfully treat a patient with advanced cancer, completely halting disease progression. This new development represents a big step forward in personalized medicine.
› Verified 7 days ago
Dr. Michael J Mahon, D.O. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 21141 Middlebelt Rd, Farmington Hills, MI 48336 Phone: 248-477-7022 Fax: 248-477-9370 | |
John Cheng Pui, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 28050 Grand River Ave, Farmington Hills, MI 48336 Phone: 248-471-8238 Fax: 248-471-8250 | |
Jon Blum, M.D. Dermatology Medicare: Medicare Enrolled Practice Location: 32905 W 12 Mile Rd, Suite 330, Farmington Hills, MI 48334 Phone: 248-553-4944 | |
Nathanial William Hansen, DO Dermatology Medicare: Medicare Enrolled Practice Location: 28050 Grand River Ave, Farmington Hills, MI 48336 Phone: 947-521-8000 | |
Trevor Alexander Nessel, DO Dermatology Medicare: Medicare Enrolled Practice Location: 28050 Grand River Ave Ofc, Farmington Hills, MI 48336 Phone: 947-521-8000 | |
Dr. Elizabeth H Michels, MD Dermatology Medicare: Medicare Enrolled Practice Location: 32905 W 12 Mile Rd, Ste 330, Farmington Hills, MI 48334 Phone: 248-553-2900 Fax: 248-553-7546 | |
Dr. Lorna Lacen Thomas, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 30445 Northwestern Hwy, Ste 142, Farmington Hills, MI 48334 Phone: 313-874-2500 Fax: 248-702-0902 |